Climb Bio, Inc. (CLYM)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $10.31
- As of
Kresmion compiles this page from CLYM's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Climb Bio, Inc. (CLYM): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-03.
See the full CLYM dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for CLYM on one page. Preview it with sample data, then open it live with a free account.
Preview the CLYM dossierActive signals for CLYM
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +443% to CLYM (2026Q2)
- mediumNEW_POSITION
D. E. Shaw & Co., Inc. new position in CLYM
- highINSTITUTIONAL_EXIT
TWO SIGMA INVESTMENTS, LP cut 52% of CLYM (2026Q2)
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 17.4%, EPS $-0.18 vs $-0.2178 estimate
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 92% of CLYM (2026Q1)
FREE, NO ACCOUNT
Every signal on CLYM, as it fires
You are seeing 5 of 11 signals recorded on CLYM since 2026-06-09.
The five above landed across 3 days. The other 6 were recorded on 2 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in CLYM (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 28658R106 · 2026Q2 | $16.9M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 28658R106 · 2026Q2 | $11.8M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 28658R106 · 2026Q2 | $2.5M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 28658R106 · 2026Q2 | $1.9M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 28658R106 · 2026Q2 | $376K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, CLYM
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
CLYM against its peers
CLYM's return on equity of -37.3% ranks in the 61st percentile of 21 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | CLYM | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 59.5M | n/a | 16 |
| Gross margin | n/a | 87.1% | n/a | 5 |
| Operating margin | n/a | -91.4% | n/a | 17 |
| Net margin | n/a | -126.3% | n/a | 17 |
| Return on equity | -37.3% | -59.2% | 61 | 21 |
| 1 year | 415.5% | -3.0% | 98 | 20 |
Peers (23): IRWD, AURA, STTK, SGMT, DBVT, WVE, OLMA, NVCT, PRME, PHAT, CRMD, ZVRA, VALN, PHAR, CTMX, VSTM, SLN, MDXG, XOMA, CADL, FDMT, SLDB, CBIO. Left out: BLSM (no annual filing), ETRA (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (CLYM: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow CLYM on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to CLYM for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.